Bio Special Special Report
Ascletis’ ASC30 SQ Injection Shows 36-Day Half-Life in Phase Ib Obesity Trial
-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...
April 01, 2025 | News
Hyundai ADM Bio Penetrium Shows Strong Anti Metastatic Efficacy in TNBC Study
Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significan...
March 28, 2025 | News
CJ BIO’s BiomeNrich™ POST M005 Becomes First Akkermansia muciniphila-Based Ingredient to Gain FDA NDIN Acknowledgment
CJ BIO's BiomeNrich™ POST M005 is the first Akkermansia muciniphila-based ingredient to receive New Dietary Ingredient Notification (NDIN) ...
March 28, 2025 | News
Singapore’s NUS Researchers Develop Dual Microneedle Technologies to Accelerate Healing of Diabetic Wounds
Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are marked by persistent inflammati...
March 27, 2025 | News
Vaximm Reports Promising Final Data from Phase 2a Trial of Oral Vaccine VXM01 with Avelumab in Recurrent Glioblastoma
Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, announced fina...
March 27, 2025 | News
China’s Innovent Doses First Patient in Phase 3 Trial of HER2-Targeted ADC for Ovarian Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
March 25, 2025 | Report
Akeso Showcases Positive Phase III Safety Run-In Data for Cadonilimab at SGO 2025 in Locally Advanced Cervical Cancer
Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...
March 24, 2025 | Report
Dizal to Present New Findings on Golidocitinib-PD-1 Combo and Sunvozertinib-Anlotinib Therapy at ELCC 2025
Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced ...
March 21, 2025 | News
Zhejiang Doer Biologics Completes Phase 2 Enrollment for First-in-Class Tri-Agonist DR10624 in Severe Hypertriglyceridemia
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...
March 11, 2025 | News
Fosun Pharma’s Foritinib Secures NMPA Nod for ALK+ NSCLC with Strong CNS Control and Improved Safety
Fosun Pharma announced that the National Medical Products Administration (NMPA) has officially accepted the marketing authorization application for Foritin...
March 10, 2025 | News
Japan’s AMR Response 2013–2025: Key Lessons and Global Implications
The World Health Organization (WHO) Regional Office for the Western Pacific (WPRO) has released Japan’s AMR Response 2013–2025, providing a com...
February 26, 2025 | News
Kangpu Biopharma Secures China IND Approval for KPG-818 in Relapsed/Refractory Multiple Myeloma
Kangpu Biopharmaceuticals, Ltd. ("Kangpu") announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National...
February 26, 2025 | News
Innovent’s Ipilimumab NDA Accepted by China’s NMPA with Priority Review for MSI-H/dMMR Colon Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
February 25, 2025 | News
Sanyou Bio Advances Drug Discovery with 10-Trillion Molecule Platform
Sanyou Biopharmaceuticals Co., Ltd. (Sanyou Bio), a world-leading biotechnology company specializing in innovative biologic drug research and development, ...
February 24, 2025 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
